Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H40N4O8 |
Molecular Weight | 596.6713 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)COC1=C(C)C=CC=C1)C(=O)N[C@@H](CC2=CC=C(OC(=O)N3CCC(CC3)C(N)=O)C=C2)C(O)=O
InChI
InChIKey=RZMCXMNNXGCFQG-DQEYMECFSA-N
InChI=1S/C31H40N4O8/c1-19(2)16-24(33-27(36)18-42-26-7-5-4-6-20(26)3)29(38)34-25(30(39)40)17-21-8-10-23(11-9-21)43-31(41)35-14-12-22(13-15-35)28(32)37/h4-11,19,22,24-25H,12-18H2,1-3H3,(H2,32,37)(H,33,36)(H,34,38)(H,39,40)/t24-,25-/m0/s1
Molecular Formula | C31H40N4O8 |
Molecular Weight | 596.6713 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:39:53 GMT 2023
by
admin
on
Sat Dec 16 10:39:53 GMT 2023
|
Record UNII |
H9W4YH429K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
278598-52-0
Created by
admin on Sat Dec 16 10:39:53 GMT 2023 , Edited by admin on Sat Dec 16 10:39:53 GMT 2023
|
PRIMARY | |||
|
9809516
Created by
admin on Sat Dec 16 10:39:53 GMT 2023 , Edited by admin on Sat Dec 16 10:39:53 GMT 2023
|
PRIMARY | |||
|
H9W4YH429K
Created by
admin on Sat Dec 16 10:39:53 GMT 2023 , Edited by admin on Sat Dec 16 10:39:53 GMT 2023
|
PRIMARY | |||
|
DB06508
Created by
admin on Sat Dec 16 10:39:53 GMT 2023 , Edited by admin on Sat Dec 16 10:39:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Anti-asthmatic; Mechanism of Action: Integrin alpha4beta1 antagonists; Highest Development Phase: Discontinued for Allergic rhinitis and Asthma
|